883

-3 0 GIU 2014

PROGETTO DI RICERCA SULLO STUDIO DELLE MALATTIE EREDITARIE DEL METABOLSIMO NEL BAMBINO
ANNO 2013

"Progetto di diagnosi precoce delle mucopolisaccaridosi e delle malattie da accumulo lisosomiale nel bambino mediante dosaggi in Spettrometria di Massa Tandem" e "Utilità degli anticorpi anti-actina in combinazione con le nuove linee guida ESPGHAN per la diagnosi della malattia celiaca"

Il Responsabile Scientifico

Prof. Paolo Moi

Progetto di diagnosi precoce delle mucopolisaccaridosi e delle malattie da accumulo lisosomiale nel bambino e nell'adulto mediante dosaggi in Spettrometria di Massa Tandem

Il progetto di screening delle malattie da accumulo lisosomiale mediante tecnologia di Spettrometria di Massa Tandem, portato avanti nell'anno 2012, ha come naturale continuità questo progetto per 2013 nel quale la diagnostica verrà ampliata alle mucopolisaccaridosi.

Le mucopolisaccaridosi sono un ampio ed eterogeneo gruppo di malattie da accumulo lisosomiale e presentano una storia clinica simile alle malattie fino ad ora studiate. Infatti anche in questo caso abbiamo un progressivo ed inesorabile accumulo di sostanze (mucopolisaccaridi o glucosaminoglicani) che determinano un progressivo ed irreversibile danno a carico di diversi organi ed apparati.

Tali malattie fino ad ora specifiche del bambino, si è recentemente evidenziato possano essere anche malattie dell'adulto, infatti esistono forme più lievi di difficile diagnosi e questo in quanto il medico dell'adulto non è abituato a pensare in termini di malattia genetica e difficilmente riesce ad individuarle.

A questo scopo il progetto prevede il coinvolgimento sia dei pediatri ma anche dei medici dell'adulto nell' invio di campioni di pazienti con sospetta mucopolisaccaridosi.

A questo scopo è prevista la stampa di brochure divulgative che permettano al medico anche non specialista di soffermarsi facilmente su sintomi di sospetto di mucopolisaccaridosi nei propri pazienti. Questo materiale informativo verrà diffuso nell'ambito degli incontri di aggiornamento dei medici pediatri e dell'adulto (medici di medicina generale e specialisti).

I campioni utilizzati per la diagnosi saranno campioni di urine (che potranno viaggiare a temperatura ambiente essendo i glucasaminoglicani non deperibili a temperatura ambiente) e raggiungere il nostro laboratorio.

Il nostro progetto prevede il dosaggio di queste sostanze in spettrometria di massa e la successiva conferma diagnostica mediante il dosaggio dell'enzima carente sempre in spettrometria di massa su sangue adsorbito su Guthrie card come nelle altre malattie da accumulo lisosomiale.

Il dosaggio dei glucosaminoglicani permette di sospettare un determinato sottotipo di mucopolisaccaridosi (in base all'accumulo di dermatansolfato, eparansolfato o cheratansolfato) e solo il dosaggio dell'enzima specifico permetterà la diagnosi definitiva.

Il progetto prevede in particolare due figure professionali per la realizzazione grafica del materiale informativo (brochure, locandine) da diffondere in apposite sedi in ambito regionale al fine di diffondere e far conoscere i più comuni sintomi di sospetto nelle diverse forme di mucopolisaccaridosi e per la gestione informatizzata della raccolta dei campioni. Tale personale verrà inoltre impiegato per la gestione informatizzata dello screening neonatale esteso. Infatti nel 2012 è stato acquisito mediante finanziamento regionale un software che permette la gestione delle anagrafiche dei campioni dello screening neonatale. Questo software consente in particolare anche la tracciabilità del campione dall'invio dal Centro fino alla ricezione del campione e alla refertazione del risultato dell'analisi.

J Pediatr. 2013 Mar 1. pii: S0022-3476(13)00065-6. doi: 10.1016/j.jpeds.2013.01.031
Identification of Infants at Risk for Developing Fabry, Pompe, or Mucopolysaccharidosis-I from Newborn Blood Spots by Tandem Mass Spectrometry.
Scott CR, Elliott S, Buroker N, Thomas LI, Keutzer J, Glass M, Gelb MH, Turecek F.

Curr Protoc Hum Genet. 2013;Chapter 17:Unit 17.12. doi: 10.1002/0471142905.hg1712s76.
Quantification of glycosaminoglycans in urine by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry.
Zhang H, Young SP, Millington DS. Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.

Utilità degli anticorpi anti-actina in combinazione con le nuove linee guida ESPGHAN per la diagnosi della malattia celiaca

4

Premessa:

Abbiamo recentemente dimostrato mediante analisi retrospettiva che gli anticorpi anti-actina filamentosa (AAA) possono essere utili a migliorare il potere predittivo dell'algoritmo ESPGHAN che consente di fare diagnosi di malattia celiaca senza necessariamente praticare la biopsia duodenale (vedi pubblicazione allegata).

Per il 2013 vogliamo invece avviare una analisi prospettica per dimostrare in modo inequivocabile la sua applicazione.

Prevediamo quindi di avvalerci della collaborazione di tre biologhe che eseguano tra altri esami indispensabili per un normale funzionamento del laboratorio anche gli esami indispensabili per applicare il nostro algoritmo per la diagnosi di malattia celiaca senza esecuzione della biopsia duodenale: la determinazione degli anticorpi anti-transglutaminasi, degli anticorpi anti actina filamentosa e del rischio genetico per malattia celiaca.

ORIGINAL ARTICLE

Utility of Anti-actin Iga Antibody in Combination with the New ESPGHAN Guidelines for Coeliac Disease Diagnosis

Enrico Schirru, Fabrice Danjou, Lucia Cicotto, Maria Paola Musu, Fulvia Frau, Stefano De Virgiliis, Rossano Rossino, Maria Doloretta Macis, Rosanna Lampis, Rita-Désirée Jores, Mauro Congia

Enrico Schirru, Department di Sanità Pubblica, Medicina Clinica e Molecolare, University of Cagliari, Cittadella Universitaria, 09045 Monserrato Cagliari, Italy

Fabrice Danjou, Department di Sanità Pubblica, Medicina Clinica e Molecolare, University of Cagliari, Cittadella Universitaria, 09045 Monserrato Cagliari, Italy

Lucia Cicotto, Gastroenterology Unit, Microcitemico Hospital, ASL8 Cagliari, Via Jenner, 09121, Cagliari, Italy

Maria Paola Musu, Department di Sanità Pubblica, Medicina Clinica e Molecolare, University of Cagliari, Cittadella Universitaria. 09045 Monserrato Cagliari, Italy

Fulvia Frau, Department di Sanità Pubblica, Medicina Clinica e Molecolare, University of Cagliari, Cittadella Universitaria, 09045 Monserrato Cagliari, Italy

Stefano De Virgiliis, Department di Scienze Chirurgiche, University of Cagliari, Via Ospedale 119, 09124, Cagliari, Italy

Rossano Rossino, Department di Sanità Pubblica, Medicina Clinica e Molecolare, University of Cagliari, Cittadella Universitaria, 09045 Monserrato Cagliari, Italy

Maria Doloretta Macis, Department di Sanità Pubblica, Medicina Clinica e Molecolare, University of Cagliari, Cittadella Universitaria, 09045 Monserrato Cagliari, Italy

Rosanna Lampis, Department di Sanità Pubblica, Medicina Clinica e Molecolare, University of Cagliari, Cittadella Universitaria, 09045 Monserrato Cagliari, Italy

Rita-Désirée Jores, Department di Sanità Pubblica, Medicina Clinica e Molecolare, University of Cagliari, Cittadella Universitaria, 09045 Monserrato Cagliari, Italy

Mauro Congia, Gastroenterology Unit, Microcitemico Hospital, ASL8 Cagliari, Via Jenner, 09121, Cagliari, Italy

Correspondence to: Mauro Congia, Gastroenterology Unit, Microcitemico Hospital, ASL8, Cagliari, Via Jenner, 09121, Cagliari, Italy. mcongia@mcweb.unica.it
Telephone: +039-070-6095522   Fax: +039-070-609-5558
Received: November 6, 2012   Revised: February 15, 2013
Accepted: February 18, 2013
Published online: May 21, 2013

ABSTRACT

AIM: An option to reduce the number of duodenal biopsies in the diagnosis of coeliac disease (CD) has recently been reported by the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition. New criteria showed that the duodenal biopsy may be avoided in presence of symptoms, high anti-transglutaminase type 2 antibody (anti-TG2) levels, anti-endomysial antibodies (EMA) and at-risk HLA, whilst biopsy still remains mandatory for individuals with moderate and low anti-TG2 levels. In this study, we considered the addition of serum measurement of anti-actin IgA antibody (AAA-IgA) to the new criteria, with the aim of further reducing the number of duodenal biopsies.

METHODS: One hundred and forty consecutive symptomatic CD children and 78 controls were studied. All subjects were classified according to the new criteria with the addition of AAA-IgA levels and results were compared with the outcome of duodenal biopsy.

RESULTS: The biopsies from the sixty-four individuals (out of 218) identified by the new criteria, presence of symptoms, anti-TG2 levels >10 times upper limit of normal (ULN), positive EMA and at-risk HLA, showed CD with a Marsh 3 lesion. In the remaining individuals, the addition of AAA-IgA allowed the detection of further 20 CD patients with a Marsh 3 damage when moderate (4 to 10 times ULN) but not low anti-TG2 levels were present.

CONCLUSIONS: Our study confirms that the new criteria may avoid the duodenal biopsy in many CD patients. Moreover, although our finding needs to be confirmed, positivity for AAA-IgA may further reduce the number of duodenal biopsies in moderate anti-TG2 levels.

INTRODUCTION

Coeliac disease (CD), is an immune-mediated systemic disease triggered and maintained by dietary gluten in genetically predisposed individuals, characterized by a variable small intestinal villous damage and by different clinical manifestations[1].

In the last 15 years, the knowledge of the disease mechanisms has increased with the discovery of the autoantigen in CD, tissue

transglutaminase type 2, and its antibody (anti-TG2) and of a multitude of different genes by Genome Wide Association Studies (GWAS) with the human leukocyte antigen HLA-DQ2 and HLA-DQ8 being the most strongly associated[1].

Recently, a synopsis summarizing some of the evidence statements and recommendations of the guidelines in CD diagnosis for use in clinical practice has been formulated by a working group within the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN)[3].

An important statement of these guidelines is the development of two new algorithms for CD diagnosis which consider as starting point (1) the presence of symptoms and signs suggestive of CD in children and adolescents (algorithm 1) and (2) the absence of symptoms and signs in persons at genetic risk for developing CD (algorithm 2).

We have considered in the present work the most interesting of the algorithms, algorithm 1: it allows the diagnosis of CD without performing the duodenal biopsy for those children and adolescents with symptoms and signs suggestive of CD, anti-TG2 levels>10 times upper limit of normal (ULN), positive confirmation tests of anti-endomisium-IgA antibodies (EMA) and with the presence of at-risk HLA-DQ2 or -DQ8.

If all these requirements were fulfilled, the diagnosis of CD is confirmed, gluten free diet is started and the patient is studied for improvement of symptoms and decline of autoantibodies. A later gluten challenge in these patients is not required[3].

However, it has been established that symptomatic CD patients with elevated degrees of intestinal damage may also been found among those with anti-TG2 levels lower than 10 times ULN[4,5]. Therefore, a high number of symptomatic CD patients with anti-TG2 levels lower than 10 times ULN, not enclosable within algorithm 1, still necessitate a duodenal biopsy.

Since anti-actin IgA antibodies (AAA-IgA) directed against actin filaments are strongly correlated with total or subtotal intestinal atrophy[6,7], we hypothesized that serum measuring of this autoantibody could contribute in increasing the number of patients who could avoid the duodenal biopsy.

This study considered the addition of serum measurement of AAA-IgA to algorithm 1, with the aim of further reducing the number of duodenal biopsies.

MATERIALS

Patients

Our group consisted of 150 consecutive Sardinian CD patients (115 females, 35 males, ratio females/males 3.3, mean age at diagnosis 8 years, range from 2 to 18 years); 140 presented symptoms suggestive of CD (Table 1) whilst 10 were not included in the study because asymptomatic and for this reason the algorithm 1 of Husby et al was not applicable. In addition, 5 patients with IgA deficiency, a well-known condition complicating the interpretation of the serological pattern of CD, were not included in the study. All patients were diagnosed according ESPGHAN criteria[8] and were recruited from a larger number of 5680 subjects attending the ambulatory of the Pediatric Gastroenterological Unit in Cagliari, Italy between 2005-2011. A further group of 78 individuals with persistent significant gastrointestinal symptoms, already characterized by upper digestive endoscopy and small bowel biopsy[7], were used as non-CD subjects. All 218 individuals were characterized for histopathology, anti-TG2, EMA, HLA typing and AAA-IgA.

Anti-TG2

Anti-TG2 was determined using the ELIA commercial kits

Table 1 Prevalence of the symptoms suggestive of CD in our cohort of children and adolescents.

Symptoms	CD patients, n (%)
Diarrhoea	39 (27.8%)
Iron deficiency anaemia	23 (16.4%)
Short stature/growth failure	23 (16.4%)
Abdominal pain	21 (15%)
Weight loss	9 (6.4%)
Chronic fatigue	8 (5.7%)
Constipation	7 (5.0%)
Vomiting	4 (2.9%)
Increased level of liver enzymes	4 (2.9%)
Irritability	2 (1.4%)

ImmunoCAP (Phadia, Milan, Italy) after serum dilution when necessary. Results were expressed in times upper limit of normal with a cut-off of 7 U/mL.

EMA

EMA was determined by immunofluorescence (Delta Biologicals, Rome, Italy). Results were expressed as intensity of immunofluorescence from 0 to 4. With the aim of reducing false positives, only strong immunofluorescence intensity (fluorescence of 2 or higher) was considered positive.

HLA typing

To type for HLA-DRB1 and -DQB1 alleles[9], HLA Olerup SSP Molecular Typing Kits (Roche, Sweden) were used according to the manufacturer's instructions. The identification of the various DRB1, DQA1, DQB1 haplotypes in CD patients was performed following the segregation of HLA haplotypes in families[10]. In this study, the two forms of HLA-DQ2, termed DQ2.5 and DQ2.2 respectively, were considered separately as the risk of DQ2.2 molecule for coeliac disease is lower than DQ2.5, unless it is expressed together with DQ2.5[11,12].

AAA-IgA

AAA-IgA is an immunofluorescence-based serological test developed in our laboratory, which has been validated in a multicenter study[6,7] as a useful marker of an elevated grade of intestinal damage associated with CD. Results were expressed by immunofluorescence intensity from 0 to 4. To reduce false positives, only strong fluorescence intensity (2 or higher) was considered positive.

Histopathology

For each patient, 2 or more biopsies were taken from the second/third portion of the duodenum (at least 4 samples), and at least 1 biopsy was taken from the duodenal bulb[3,13]. Intestinal villous atrophy has been graded according to the Marsh classification[14] modified by Oberhuber in type 3c, 3b and 3a 2, 1 and 0[15], always by the same board-certified pathologists.

Statistical analysis

The frequencies of outcomes were analyzed using the chi square test where appropriate. A p value <0.05 was considered significant.

RESULTS

The one hundred and forty CD patients and 78 controls were classified according to the presence of symptoms and signs suggestive of CD, anti-TG2 levels, positivity for EMA and for HLA-DQ2 (in cis or in trans) or -DQ8 as recently reported by Husby et al[3] (Figure 1). Among the CD patients, the histopathology according to Marsh-Oberhuber classification[14,15] showed a type 3c lesion in 57, type 3b in 44, type 3a in 16, type 2 in 2, type 1 in 4 and type 0

Figure 3 Distribution of AAA-IgA in the 34 subjects of subgroup 3 with anti-TG2 levels comprised between 4 and 10 ULN. CD: coeliac disease; anti-TG2: anti-transglutaminase type 2 antibody; ULN: upper limit of normal; EMA: anti-endomysial antibodies; HLA: human leukocyte antigen; 3a, 3b, 3c, 2, 1 and 0 indicate the grade of intestinal damage according to the Marsh-Oberhuber classification[14,15]; GFD: gluten free diet; OEGD: oesophagogastroduodenoscopy; F/u: follow-up; AAA-IgA: anti-actin IgA antibody.

DISCUSSION

The new algorithm 1 recently reported by ESPGHAN suggested that in the diagnosis of CD, the duodenal biopsies could be avoided in children and adolescents with CD associated symptoms, high anti-TG2 levels, positivity for EMA and at-risk HLA. The aims of the present study were to confirm the reliability of algorithm 1 and to reduce further the number of duodenal biopsies by adding the serum measurement of another marker of intestinal damage (AAA-IgA)[7,16,17].

In our cohort we found that the new algorithm would have avoided the duodenal biopsy in 64 out of 140 CD patients (Subgroup 1 of figure 1). We also found that all the 64 CD patients had a Marsh 3 grade of intestinal damage. This finding confirms, as previously suggested, that anti-TG2 level > 10 times ULN is strongly associated with the most severe intestinal damages[18,19]. On the other hand, we noticed that the algorithm 1 was not able to detect with a sufficient accuracy a Marsh 3 damage when the values of anti-TG2 were lower than 10 times ULN. In fact, among the 73 subjects of subgroup 3 (differing from subgroup 1 only for anti-TG2 levels less than 10 times ULN) a variable degree of intestinal damage ranging from a Marsh 3 lesion to only an isolated increment in the number of intraepithelial lymphocytes was found.

Since numerous studies have reported a strong association of AAA-IgA with a severe CD intestinal damage[7,16,17] and since the likelihood of CD is unequivocal when a villous atrophy of Marsh 3 is found[14,15], we measured the AAA-IgA in the subgroups 1, 3 and 5, with the aim to identify subjects with Marsh 3 intestinal histopathology. The most important result comes from the measurement of AAA-IgA in subgroup 3 in which positivity for AAA-IgA and a Marsh 3 lesion was restricted to subjects having a level of anti-TG2 antibody between 4 and 10 times ULN (Figure 3). Conversely, the addition of AAA-IgA to subjects with anti-TG2 level > 10 times ULN (subgroup 1) did not increase the number of patients already identified by algorithm 1 (Table 2). We also noticed that AAA-IgA was not unequivocally associated with a Marsh 3 histopathology in individuals with anti-TG2 levels less than 4 times ULN. Indeed, three CD patients of subgroup 3 (one with grade Marsh

0; two with Marsh 1) and three controls (Subgroup 5) were found AAA-IgA positive.

In total, adding AAA-IgA in the algorithm allowed the identification of 20 additional CD patients with a Marsh 3 lesion (Figure 3), thus increasing from 64 (45% of sensitivity and 100% of specificity of the algorithm 1) to 84 (60% of sensitivity and 100% of specificity of the algorithm 1 plus serum AAA-IgA measurement) the total number of patients in whom duodenal biopsies could have been avoided.

Although a wide range of sensitivity and specificity values of AAA-IgA have been reported, questioning its utility in the screening for CD[20], our data suggest that the best manner of using AAA-IgA measurement in the diagnosis of CD is not as an isolated test, neither when anti-TG2 antibody has a titer higher than 10 times ULN (the association with a Marsh 3 lesion is complete and no other test should be requested) nor when anti-TG2 has a titer lower than 4 times ULN (it has been shown that low values of anti-TG2 positivity are found also in non-CD patients affected by other autoimmune pathologies as well as infections, tumors, myocardial damage, liver disorders, and psoriasis[21,22]), but in the restricted number of patients having moderate values comprised between 4 and 10 times ULN.

Recently, strong positive Red Blood Cells - anti-TG2 (RBC-TG2ab) values have been shown to correlate very well with EMA and human recombinant anti-TG2 (Hr-TG2ab) and with positivity of DQ2/8, making it possible to establish the diagnosis of CD in 94% of both children and adults belonging to at-risk groups[23]. In contrast, moderately positive RBC-TG2ab showed poor correlation with the other tests, and the diagnosis of CD was formulated in only 69% of children and 86% of adults[23]. Our findings suggest that AAA-IgA could also be helpful in improving the diagnosis of CD in this setting: children and adults belonging to at-risk groups with moderately positive RBC-TG2ab levels.

In conclusion, our findings confirm that the duodenal biopsy may be omitted in a significant number of CD patients with the application of algorithm 1 as suggested by Husby et al[3]. In addition, we show that positivity for AAA-IgA in children and adolescents with anti-TG2 antibody comprised between 4 and 10 times ULN may further reduce the number of duodenal biopsies.

ACKNOWLEDGMENTS

REFERENCES

1   Green PH, Cellier C. Celiac disease. N Engl J Med 2007; 357: 1731-1743
2   Tack GJ, Verbeek WH, Schreurs MW, Mulder CJ. The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol 2010; 7: 204-213
3   Husby S, Koletzko S, Korponay-Szabo IR, Mearin ML, Phillips A, Shamir R, Troncone R, Giersiepen K, Branski D, Catassi C, Lelgeman M, Maki M, Ribes-Koninckx C, Ventura A, Zimmer KP. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines for the Diagnosis of Coeliac Disease. J Pediatr Gastroenterol Nutr 2012; 54: 136-160
4   Donaldson MR, Firth SD, Wimpee H, Leiferman KM, Zone JJ, Horsley W, O'Gorman MA, Jackson WD, Neuhausen SL, Hull CM, Book LS. Correlation of duodenal histology with tissue transglutaminase and endomysial antibody levels in pediatric celiac disease. Clin Gastroenterol Hepatol 2007; 5: 567-573
5   Hopper AD, Hadjivassiliou M, Hurlstone DP, Lobo AJ,

Figure 1 Distribution of 140 CD patients and 78 controls according to the algorithm 1 proposed by Husby et al. For each of the 5 subgroups the degree of intestinal atrophy is also illustrated. CD: coeliac disease; anti-TG2: anti-transglutaminase type 2 antibody; ULN: upper limit of normal; EMA: anti-endomysial antibodies; HLA: human leukocyte antigen; 3a, 3b, 3c, 2, 1 and 0 indicate the grade of intestinal damage according to the Marsh-Oberhuber classification[14,15]; GFD: gluten free diet; OEGD: oesophagogastroduodenoscopy; F/u: follow-up; AAA-IgA: anti-actin IgA antibody.


Figure 2 Measurement of AAA-IgA among the 73 subjects of subgroup 3. CD: coeliac disease; anti-TG2: anti-transglutaminase type 2 antibody; ULN: upper limit of normal; EMA: anti-endomysial antibodies; HLA: human leukocyte antigen; 3a, 3b, 3c, 2, 1 and 0 indicate the grade of intestinal damage according to the Marsh-Oberhuber classification[14,15]; AAA-IgA: anti-actin IgA antibody.

in 17 potential CD patients, whilst in all 78 controls with persistent significant gastrointestinal symptoms the duodenal histopathological signs associated with CD were not found.

The application of algorithm 1 to our cohort of patients and controls generated 5 different subgroups. The 5 subgroups and the degrees of intestinal damage associated to them are showed in figure 1.

We found that out of the 218 individuals studied, all 64 with symptoms and signs suggestive of CD, anti-TG2 levels >10 times ULN, positivity for EMA and for HLA-DQ2 (in *cis* or in *trans*) or -DQ8, showed a coeliac disease with a Marsh 3 atrophy (Subgroup 1 of figure 1).

As far as the HLA associated risk was concerned, three out of the 218 were found to express the DQ2.2 molecule without DQ2.5. One of them had anti-TG2 level higher than 10 times ULN and fell in the subgroup 2, whereas the remaining two patients, considering their anti-TG2 level lower than 10 times ULN, were included in the subgroup 4 (Figure 1). The patient of subgroup two showed Marsh 3c histopathology, whilst the two of the subgroup 4 showed Marsh 0 and were thus classified as potential CD (Figure 1).

Among the 218, seventy-three coeliac disease patients were included in the subgroup 3, that differed from the subgroup 1 only for

the anti-TG2 levels lower than 10 times ULN (Figure 1).

The remaining subgroup five was constituted by the seventy-eight controls (Figure 1).

Based on these data, the association of AAA-IgA with severe intestinal damage was evaluated in the subgroups one, three and five. Subgroups two and four were not considered further because the low number of patients included in these groups did not consent to draw conclusions.

As expected, since AAA-IgA is a marker of severe intestinal damage, a higher frequency of AAA-IgA positive individuals was found in subgroups one and three that included the CD patients compared to subgroup five that included controls (Table 2). However, we found that in subgroup one, the addition of AAA-IgA to the outcome of the algorithm 1 did not offer any further useful information as only 76.5% of the CD patients, already defined by algorithm 1, were AAA-IgA positive (Table 2).

Conversely, in subgroup three the positivity for AAA-IgA correlated significantly (OR=10.45; $p<0.05$) with Marsh 3 histopathology (Figure 2). This association became even more elevated when increasing the cut-off level of anti-TG2. In fact, an unequivocal association between positivity for AAA-IgA and Marsh 3 histopathology was observed in patients with an anti-TG2 level less than 10 times ULN but higher than 4 times ULN (Figure 3). Using this strategy, further 20 CD patients of subgroup three were confirmed to have a Marsh 3 histopathology (Figure 3).

Finally, in subgroup five only 3 out of 78 controls were AAA-IgA positive (Table 2).

Table 2 Distribution of positive AAA-IgA among subgroups obtained with the algorithm 1 of Husby *et al*[1].

Intestinal atrophy according to the Marsh/ Oberhuber classification	Subgroup 1	Subgroup 3	Subgroup 5
	AAA-IgA+/ Alg. 1 (%)	AAA-IgA+/ Alg. 1 (%)	AAA-IgA+/ Alg. 1 (%)
3c	30/36 (83.3)	15/20 (75)	/
3b	18/21 (85.7)	14/23 (60.8)	/
3a	1/7 (14.2)	1/9 (11.1)	/
0-1-2	/	3/21 (14.2)	3/78 (3.8)
Total	49/64 (76.5)	33/73 (45.2)	3/78 (3.8)

[1] Subgroups two and three were not considered because the low number of patients

8

McAlindon ME, Egner W, Wild G, Sanders DS. What is the role of serologic testing in celiac disease? A prospective, biopsy-confirmed study with economic analysis. *Clin Gastroenterol Hepatol* 2008; 6: 314-320

6   Clemente MG, Musu MP, Frau F, Brusco G, Sole G, Corazza GR, De Virgiliis S. Immune reaction against the cytoskeleton in coeliac disease. *Gut* 2000; 47: 520-526

7   Clemente MG, Musu MP, Troncone R, Volta U, Congia M, Ciacci C, Neri E, Not T, Maggiore G, Strisciuglio P, Corazza GR, Gasbarrini G, Cicotto L, Sole G, Fasano A, De Virgiliis S. Enterocyte actin autoantibody detection: a new diagnostic tool in celiac disease diagnosis: results of a multicenter study. *Am J Gastroenterol* 2004; 99: 1551-1556

8   Walker-Smith J, Guandalini, S, Schmitz, J, Shmerling, DH,, Visakorpi J. Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. *Arch Dis Child* 1990; 65: 909-911

9   Olerup O, Zetterquist H. HLA-DRB1*01 subtyping by allele-specific PCR amplification: a sensitive, specific and rapid technique. *Tissue Antigens* 1991; 37: 197-204

10 Lampis R, Morelli L, De Virgiliis S, Congia M, Cucca F. The distribution of HLA class II haplotypes reveals that the Sardinian population is genetically differentiated from the other Caucasian populations. *Tissue Antigens* 2000; 56: 515-521

11 Abrams JA, Brar P, Diamond B, Rotterdam H, Green PH. Utility in clinical practice of immunoglobulin a anti-tissue transglutaminase antibody for the diagnosis of celiac disease. *Clin Gastroenterol Hepatol* 2006; 4: 726-730

12 Vader W, Stepniak D, Kooy Y, Mearin L, Thompson A, van Rood JJ, Spaenij L, Koning F. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. *Proc Natl Acad Sci U S A* 2003; 100: 12390-123905

13 Pais WP, Duerksen DR, Pettigrew NM, Bernstein CN. How many duodenal biopsy specimens are required to make a diagnosis of celiac disease? *Gastrointest Endosc* 2008; 67: 1082-1087

14 Marsh MN, Crowe PT. Morphology of the mucosal lesion in gluten sensitivity. *Baillieres Clin Gastroenterol* 1995; 9: 273-293

15 Oberhuber G. Histopathology of celiac disease. *Biomed Pharmacother* 2000; 54: 368-372

16 Achour A, Thabet Y, Sakly W, Mankai A, Sakly N, Ayadi A, Sfar MT, Amri F, Harbi A, Essoussi AS, Krifa A, Ajmi S, Ghedira I. IgA anti-actin antibodies in celiac disease. *Gastroenterol Clin Biol* 2010; 34: 483-487

17 Carroccio A, Brusca I, Iacono G, Di Prima L, Teresi S, Pirrone G, Florena AM, La Chiusa SM, Averna MR. Anti-actin antibodies in celiac disease: correlation with intestinal mucosa damage and comparison of ELISA with the immunofluorescence assay. *Clin Chem* 2005; 51: 917-920

18 Hill PG, Holmes GK. Coeliac disease: a biopsy is not always necessary for diagnosis. *Aliment Pharmacol Ther* 2008; 27: 572-577

19 Dahlbom I, Korponay-Szabo IR, Kovacs JB, Szalai Z, Maki M, Hansson T. Prediction of clinical and mucosal severity of coeliac disease and dermatitis herpetiformis by quantification of IgA/IgG serum antibodies to tissue transglutaminase. *J Pediatr Gastroenterol Nutr* 2010; 50: 140-146

20 Fabbro E, Rubert L, Quaglia S, Ferrara F, Kiren V, Ventura A, Not T. Uselessness of anti-actin antibody in celiac disease screening. *Clin Chim Acta* 2008;390: 134-137

21 Bizzaro N, Tampoia M, Villalta D, Platzgummer S, Liguori M, Tozzoli R, Tonutti E. Low specificity of anti-tissue transglutaminase antibodies in patients with primary biliary cirrhosis. *J Clin Lab Anal* 2006; 20: 184-189

22 Villalta D, Bizzaro N, Tonutti E, Tozzoli R. IgG anti-transglutaminase autoantibodies in systemic lupus erythematosus and Sjogren syndrome. *Clin Chem* 2002; 48: 1133

23 Kurppa K, Salminiemi J, Ukkola A, Saavalainen P, Loytynoja K, Laurila K, Collin P, Maki M, Kaukinen K. Utility of the new ESPGHAN criteria for the diagnosis of celiac disease in at-risk groups. *J Pediatr Gastroenterol Nutr* 2012; 54: 387-391

Presidio Ospedaliero
Microcitemico

Struttura Complessa
Clinica Pediatrica 2ª
Università degli Studi di Cagliari

ASLCagliari

PIANO FINANZIARIO 2013
CONTRIBUTO PER LO STUDIO DELLE MALATTIE EREDITARIE DEL
METABOLSIMO NEL BAMBINO

"Progetto di diagnosi precoce delle mucopolisaccaridosi e delle malattie da accumulo lisosomiale nel bambino mediante dosaggi in Spettrometria di Massa Tandem" e "Utilità degli anticorpi anti-actina in combinazione con le nuove linee guida ESPGHAN per la diagnosi della malattia celiaca"

Spese per il Personale:

....110.000,00

Spese per servizi:

....41.111,75

Spese per gestione e laboratorio:

....48.888,25

Totale complessivo...€ 200.000,00

Cordiali saluti,

Il Direttore della Clinica Pediatrica 2ª
Prof. Paolo Moi

ALLEGATO ALLA DELIBERAZIONE

N. 883 DEL 3 0 GIU 2014

IL DIRETTORE AMMINISTRATIVO   IL DIRETTORE SANITARIO
(Dott. Sergio Salis)   (Dott. Ugo Storelli)
           IL DIRETTORE GENERALE
           (Dott. Emilio Simeone)

Il presente allegato è composto da n° 10 fogli
di n° 10 pagine

10